Verinurad

Verinurad
Clinical data
Other namesRDEA-3170; RDEA3170
Legal status
Legal status
  • Investigational
Identifiers
  • 2-[3-(4-Cyanonaphthalen-1-yl)pyridin-4-yl]sulfanyl-2-methylpropanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC20H16N2O2S
Molar mass348.42 g·mol−1
3D model (JSmol)
  • CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N
  • InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)
  • Key:YYBOLPLTQDKXPM-UHFFFAOYSA-N

Verinurad is a selective URAT1 inhibitor developed for gout and heart failure by AstraZeneca.[1][2][3]

  1. ^ Johansson, Susanne; Han, David; Hunt, Thomas; Björck, Karin; Florica, Delia; Gillen, Michael; Hall, Jesse; Erlandsson, Fredrik (June 2022). "Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants". Pharmacology Research & Perspectives. 10 (3): e00929. doi:10.1002/prp2.929. PMC 9121888. PMID 35593744.
  2. ^ Fitz-Patrick, David; Roberson, Kent; Niwa, Kiyoshi; Fujimura, Takabumi; Mori, Koji; Hall, Jesse; Yan, Xiaohong; Shen, Zancong; Liu, Sha; Ito, Yasushi; Baumgartner, Scott (2 November 2019). "Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials". Modern Rheumatology. 29 (6): 1042–1052. doi:10.1080/14397595.2018.1538003. PMID 30334639. S2CID 52988677.
  3. ^ Tan, Philip K.; Liu, Sha; Gunic, Esmir; Miner, Jeffrey N. (6 April 2017). "Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout". Scientific Reports. 7 (1): 665. Bibcode:2017NatSR...7..665T. doi:10.1038/s41598-017-00706-7. ISSN 2045-2322. PMC 5429603. PMID 28386072.